(20)
Ā
š¬ The Science Behind MAIA: Disrupting Telomeres to Kill Cancer
Ā
MAIAās technology is rooted in a first-in-class small molecule therapy ā ateganosine (also called THIO).
Ā
New data from ESMO 2025 reinforces this mechanism ā showing a 30-month survivor in THIO-101 and confirming
ateganosineās ability to drive durable tumor regression even in ICI-resistant patients.Ā (23)
Ā
What it does:
Ā
⢠Targets telomeres, the protective DNA caps that help cancer cells replicate endlessly
⢠It alsoĀ re-sensitizes tumors to immune attack ā making immunotherapies work again in patients who previously stopped responding
Ā
This is
especially relevant forĀ advanced non-small cell lung cancer (NSCLC)Ā ā a high-mortality cancer with limited options once frontline chemo and checkpoint inhibitors fail.
Ā
š Funding locked: $2.25M (Sept 29) + $736.6K (Oct 13) for THIO-101 Step 1Ā (21)(22)
Ā
Hereās the fresh development:
Ā
MAIA recently announced
aĀ private placement of ~1,733,766 shares at $1.30 each (with warrants at $1.57 exercisable in 6 months, valid for 3 years) to raise approxĀ $2.25 M ā the proceeds earmarked to fund Step 1 of Part C in its Phase II THIO-101 trial.Ā Ā
Ā
Shares priced atĀ $1.30, alongside warrants atĀ $1.57
Ā
Warrants are exercisable in six months and last for 3
years
Ā
One participant is aĀ company director ā signaling internal confidence
Ā
This raise didnāt come cheap ā and it didnāt come from tourists. Itās a strong sign that MAIA intends to accelerate, not wait.
Ā
And with the chart moving right around the raise price,Ā momentum chasers are watching closely.
Ā
𧬠NIH Co-Sign + FDA Fast Track = Major
De-Risking
Ā
This isnāt just a pipeline story anymore ā itās a story with federal and regulatory validation.
Ā
ā¢Ā Sept 24: $2.3M Grant from NIH ā backs U.S. patient enrollment in the THIO-101 trial.Ā (19)
ā¢Ā July 28: FDA Fast Track Status Secured ā Fast Track designation from the FDA reflects serious potential.Ā (11)Ā
Ā
āIf approved, ateganosine would have a first-to-market competitive position⦠with a potential FDA decision as early as next year.ā ā CEO Dr. Vlad Vitoc (from earlier article context)
Ā
š Analyst Targets Are Sky High
Ā
Robert LeBoyer @ Noble Life Science PartnersĀ
Target:Ā $14.00
Ā
Rationale:
Multiple checkpoint inhibitor partnerships (including Roche), improved OS and PFS, and favorable safety data
Ā
Diamond Equity ResearchĀ
Ā
Target:Ā $10.27
Ā
Cites: 17.8-month median survival in Phase 2, strong durability, and Fast Track designation
Ā
Those targets implyĀ 500%ā700%+ upside from recent levels.
Ā
āļø Trial Progress + Next Steps
Are Clear
Ā
With bothĀ NIH and private funding now secured, MAIA is moving into theĀ execution phase of its THIO-101 trial:
Ā
ā¢Ā Step 1 of Part CĀ now funded and launching
⢠U.S. patient enrollment greenlit
ā¢Ā Pivotal Phase II THIO-104 on deck for 2H 2025
⢠Accelerated approval possible in 2026, contingent on THIO-101 outcomes
Ā
This is a
high-conviction roadmap backed by government money, regulatory clearance, and now capital to move forward without delay.
Ā
š Low Float + Breakout Setup
Ā
Float:Ā ~28.3M shares
Chart: Pressing into multi-month resistance withĀ 200-day SMA near ~$1.77
Support: Holding prior lows and building higher
Ā
When technical momentum meets fresh catalysts, the setup can flip
fast.
Ā
š The Big Picture: Weāve Been Here Before
Ā
MAIA isnāt a stranger to breakout setups.
Ā
Itās back ā but this time, itās:
Ā
⢠Better funded
⢠Further along in its trial
⢠Backed by NIH
⢠Fast-tracked by the FDA
⢠Building new partnerships
⢠And attracting renewed attention from the
Street
Ā
This isnāt just a repeat. It could be bigger.
Ā
Weāve talked aboutĀ MAIA Biotechnology, Inc. (NYSE American: MAIA)Ā before. But whatās happening now feels like the next act ā and all the signals are starting to sync again.
Ā
Stay alert. Iāll keep you updated as it unfolds.
Ā
To your success,
Ā
Max Masters
Co-founder, Market Tips Newsletter
Ā
Sources:
1. https://bit.ly/4cLWaog
2. https://bit.ly/4cRuZZk
3. https://bit.ly/42pGNOM
4. https://bit.ly/4cVjJLl
5. https://bit.ly/4jmedDM
6. https://finance.yahoo.com/quote/MAIA/history/
7. https://bit.ly/4lKdluq
8. https://bit.ly/3GminNn
9. https://finance.yahoo.com/news/maia-biotechnology-announces-first-patient-131500434.html
10. https://finance.yahoo.com/news/maia-biotechnology-announces-peer-reviewed-131700117.html
11.
https://finance.yahoo.com/news/maia-biotechnology-receives-fda-fast-120100331.html
12. https://finance.yahoo.com/news/maia-biotechnology-granted-european-patent-130100345.html
13. https://finance.yahoo.com/news/diamond-equity-research-releases-note-120000909.html
14. https://ml.globenewswire.com/Resource/Download/b5e1fff3-02a0-4a78-b533-2ec8845f612e
15. https://finance.yahoo.com/news/maia-biotechnology-announces-publication-interim-130100253.html
16. https://finance.yahoo.com/news/maia-biotechnology-abstract-selected-poster-130300068.html
17. https://maiabiotech.com/
18. https://ir.maiabiotech.com/company-information/presentations
19.
https://finance.yahoo.com/news/maia-biotechnology-awarded-2-3-120100527.html
20.Ā https://ir.maiabiotech.com/
21. https://finance.yahoo.com/news/maia-biotechnology-announces-2-25-203000956.html
22. https://finance.yahoo.com/news/maia-biotechnology-announces-736-600-202000357.html
23.
https://finance.yahoo.com/news/maia-biotechnology-details-30-month-123600465.html